nafagrel has been researched along with Injury, Myocardial Reperfusion in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Endoh, A; Iimura, O; Iwamoto, T; Miura, T; Ogawa, T; Tsuchida, A; Urabe, K | 1 |
1 other study(ies) available for nafagrel and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Tissue-type plasminogen activator alone or in combination with thromboxane A2 synthetase inhibitor for ischemic myocardium.
Topics: Animals; Blood Pressure; Drug Therapy, Combination; Heart; Heart Rate; Imidazoles; Myocardial Infarction; Myocardial Reperfusion Injury; Rabbits; Tetrahydronaphthalenes; Thromboxane-A Synthase; Tissue Plasminogen Activator | 1990 |